newsNew partnership to explore potential biodefence applications for FX-064 March 2021 | By Hannah Balfour (European Pharmaceutical Review)Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.